The age variation of HER2 immunohistochemistry positive rate in biopsy specimens of gastric cancer

Ahn, 2015, Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens, Oncotarget, 6, 38372, 10.18632/oncotarget.5368 Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X Bartley, 2016, HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology, Arch. Pathol. Lab. Med., 140, 1345, 10.5858/arpa.2016-0331-CP Bosman, 2010 Chen, 2016, Cancer statistics in China, 2015, CA Cancer J. Clin., 10.3322/caac.21338 Cho, 2013, A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages, Ann. Surg. Oncol., 20, S477, 10.1245/s10434-012-2818-0 Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer Suppl., 136, E359, 10.1002/ijc.29210 Francis, 2009, Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome, Diagn. Mol. Pathol., 18, 88, 10.1097/PDM.0b013e31816f6374 Ge, 2015, Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks, Hum. Pathol., 46, 850, 10.1016/j.humpath.2015.02.011 Gomez-Martin, 2014, A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond, Cancer Lett., 351, 30, 10.1016/j.canlet.2014.05.019 He, 2013, Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer, World J. Gastroenterol., 19, 2171, 10.3748/wjg.v19.i14.2171 Hofmann, 2008, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 52, 797, 10.1111/j.1365-2559.2008.03028.x Huang, 2013, HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study, PLoS One, 8 Huang, 2016, HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance, Gastric Cancer, 19, 176, 10.1007/s10120-014-0453-0 A. Japanese Gastric Cancer, 2011, Japanese classification of gastric carcinoma: 3rd English edition, Gastric Cancer, 14, 101, 10.1007/s10120-011-0041-5 Jorgensen, 2012, HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature, J. Cancer, 3, 137, 10.7150/jca.4090 Kim, 2014, Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force, Asia. J. Clin. Oncol., 10, 297, 10.1111/ajco.12263 Kim, 2018, HER2 status in gastric and gastroesophageal junction Cancer: results of the large, multinational HER-EAGLE study, Appl. Immunohistochem. Mol. Morphol., 26, 239, 10.1097/PAI.0000000000000423 Lee, 2011, Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections, Histopathology, 59, 832, 10.1111/j.1365-2559.2011.04017.x Pirrelli, 2013, Are biopsy specimens predictive of HER2 status in gastric cancer patients?, Dig. Dis. Sci., 58, 397 Qiu, 2014, Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients, BMC Cancer, 14, 823, 10.1186/1471-2407-14-823 Ruschoff, 2012, HER2 testing in gastric cancer: a practical approach, Modern Pathol., 25, 637, 10.1038/modpathol.2011.198 Sheffield, 2014, HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation, Arch. Pathol. Lab. Med., 138, 1495, 10.5858/arpa.2013-0604-OA Sheng, 2013, HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance, Ann. Oncol., 24, 2360, 10.1093/annonc/mdt232 Torre, 2015, Global cancer statistics, 2012, CA Cancer J. Clin., 65, 87, 10.3322/caac.21262 Wang, 2014, Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status, Hum. Pathol., 45, 970, 10.1016/j.humpath.2013.12.010 Xu, 2017, Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer, Diagn. Pathol., 12, 41, 10.1186/s13000-017-0616-5 Xu, 2017, HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks, Histopathology, 10.1111/his.13257 Xu, 2017, Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type, Oncotarget, 8, 33185, 10.18632/oncotarget.16567 Yang, 2006, Incidence and mortality of gastric cancer in China, World J. Gastroenterol., 12, 17, 10.3748/wjg.v12.i1.17 Yuan, 2015, Targeted therapy for gastric cancer: current status and future directions (Review), Oncol. Rep.